MX2022008479A - Combinaciones de brimonidina de dosis baja y usos de las mismas. - Google Patents

Combinaciones de brimonidina de dosis baja y usos de las mismas.

Info

Publication number
MX2022008479A
MX2022008479A MX2022008479A MX2022008479A MX2022008479A MX 2022008479 A MX2022008479 A MX 2022008479A MX 2022008479 A MX2022008479 A MX 2022008479A MX 2022008479 A MX2022008479 A MX 2022008479A MX 2022008479 A MX2022008479 A MX 2022008479A
Authority
MX
Mexico
Prior art keywords
combinations
low
present
brimonidine
dose
Prior art date
Application number
MX2022008479A
Other languages
English (en)
Inventor
Gerald Horn
Original Assignee
Eye Therapies Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eye Therapies Llc filed Critical Eye Therapies Llc
Publication of MX2022008479A publication Critical patent/MX2022008479A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/382—Heterocyclic compounds having sulfur as a ring hetero atom having six-membered rings, e.g. thioxanthenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a composiciones que contienen brimonidina de dosis baja y ya sea un segundo fármaco para glaucoma, una anti-histamina o un fármaco anti-inflamatorio no esteroideo; la presente invención se dirige además, a métodos para tratar glaucoma o alergias o reducir la inflamación administrando composiciones de la presente invención.
MX2022008479A 2017-06-08 2019-12-06 Combinaciones de brimonidina de dosis baja y usos de las mismas. MX2022008479A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762516931P 2017-06-08 2017-06-08
US201862621082P 2018-01-24 2018-01-24

Publications (1)

Publication Number Publication Date
MX2022008479A true MX2022008479A (es) 2022-08-02

Family

ID=64562826

Family Applications (3)

Application Number Title Priority Date Filing Date
MX2019014748A MX2019014748A (es) 2017-06-08 2018-06-07 Combinaciones de brimonidina de dosis baja y usos de las mismas.
MX2022008479A MX2022008479A (es) 2017-06-08 2019-12-06 Combinaciones de brimonidina de dosis baja y usos de las mismas.
MX2022008478A MX2022008478A (es) 2017-06-08 2019-12-06 Combinaciones de brimonidina de dosis baja y usos de las mismas.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2019014748A MX2019014748A (es) 2017-06-08 2018-06-07 Combinaciones de brimonidina de dosis baja y usos de las mismas.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2022008478A MX2022008478A (es) 2017-06-08 2019-12-06 Combinaciones de brimonidina de dosis baja y usos de las mismas.

Country Status (12)

Country Link
US (2) US20180353504A1 (es)
EP (1) EP3634415A4 (es)
JP (2) JP2020523312A (es)
KR (1) KR20200018580A (es)
CN (2) CN110996954A (es)
AU (2) AU2018279074B2 (es)
BR (1) BR112019025987A2 (es)
CA (1) CA3066398A1 (es)
CL (3) CL2019003572A1 (es)
MX (3) MX2019014748A (es)
SG (1) SG11201911750RA (es)
WO (2) WO2018226942A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020009954A1 (en) 2018-07-03 2020-01-09 Fennec Pharmaceuticals, Inc. Formulations of anhydrous sodium thiosulfate
BR112022024202A2 (pt) 2020-05-27 2022-12-20 Lupin Ltd Composições oftálmicas de nano-emulsão
WO2022097731A1 (ja) * 2020-11-06 2022-05-12 アイ・セラピーズ・エル・エル・シー 眼科用液体製剤
KR102444571B1 (ko) * 2020-11-18 2022-09-19 주식회사태준제약 세티리진 및 토코페솔란을 포함하는 안과용 조성물
US20240041869A1 (en) * 2022-08-04 2024-02-08 Bausch + Lomb Ireland Limited Ophthalmic composition comprising an anti-allergen and a redness reduction agent
WO2024028816A1 (en) * 2022-08-04 2024-02-08 Bausch + Lomb Ireland Limited Ophthalmic composition comprising pilocarpine and a redness reduction agent

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7030149B2 (en) * 2002-04-19 2006-04-18 Allergan, Inc. Combination of brimonidine timolol for topical ophthalmic use
PT1534313E (pt) * 2002-07-30 2013-01-25 Omeros Corp Soluções e método de irrigação oftalmológica
CN100463668C (zh) * 2005-05-09 2009-02-25 凌沛学 可逆性热凝胶化水性药物组合物
ITMI20070890A1 (it) * 2007-05-04 2008-11-05 Sifi Spa Composizioni oftalmiche per il trattamento della ipertensione oculare e del glaucoma
BRPI0818459A2 (pt) * 2007-10-16 2015-04-14 Sun Pharma Advanced Res Co Ltd Composição farmacêutica adequada para uso oftálmico.
US20180360825A1 (en) * 2008-08-01 2018-12-20 Eye Therapies, Llc Vasoconstriction compositions and methods of use
WO2010014552A1 (en) * 2008-08-01 2010-02-04 Alpha Synergy Development, Inc. Vasoconstriction compositions and methods of use
US20100203165A1 (en) * 2008-08-01 2010-08-12 Gerald Horn Compositions and methods for treatment of disorders or conditions of the eye
MX2011009802A (es) * 2009-03-17 2011-11-02 Aciex Therapeutics Inc Formulaciones oftalmicas de cetirizina y metodos de uso.
CA2754996A1 (en) * 2009-03-17 2010-09-23 Aciex Therapeutics, Inc. Ophthalmic formulations of ketotifen and methods of use
CA2764477A1 (en) * 2009-06-05 2010-12-09 Aciex Therapeutics, Inc. Ophthalmic formulations, methods of manufacture, and methods of using same
US8445526B2 (en) * 2011-02-03 2013-05-21 Glaucoma & Nasal Therapies Llc Compositions and methods for treatment of glaucoma
CA2869280C (en) * 2011-04-05 2020-03-10 Optosolve Llp Ophthalmic treatments
US20130203813A1 (en) * 2011-05-04 2013-08-08 Johnson & Johnson Vision Care, Inc. Medical devices having homogeneous charge density and methods for making same
CN103747786A (zh) * 2011-07-20 2014-04-23 阿勒根公司 比马前列素和溴莫尼定的固定剂量组合
US20140194527A1 (en) * 2012-02-29 2014-07-10 Rohto Usa, Inc. Geranylgeranylacetone formulations and retinal delivery thereof
US9248135B2 (en) * 2012-04-24 2016-02-02 Allergan, Inc. Prostaglandin and vasoconstrictor pharmaceutical compositions and methods of use
US9833441B2 (en) * 2013-08-28 2017-12-05 Presbyopia Therapies Llc Compositions and methods for the treatment of presbyopia
US9314427B2 (en) * 2013-08-28 2016-04-19 Presbyopia Therapies Llc Compositions and methods for the improvement of distance vision and the treatment of refractive errors of the eye
US10105350B2 (en) * 2014-03-12 2018-10-23 The Trustees Of Columbia University In The City Of New York Cosmetic preservatives as therapeutic corneoscleral tissue cross-linking agents
US20180250313A1 (en) * 2015-09-08 2018-09-06 Viewpoint Therapeutics, Inc. Compounds and formulations for treating ophthalmic diseases
US9694003B2 (en) * 2015-10-15 2017-07-04 Bridge Pharma, Inc. Formulations and methods for treating high intraocular pressure
US20200197398A1 (en) * 2017-06-08 2020-06-25 Eye Therapies, Llc Netarsudil and low-dose brimonidine combination and uses thereof

Also Published As

Publication number Publication date
JP2023055823A (ja) 2023-04-18
MX2022008478A (es) 2022-08-02
AU2018279074A1 (en) 2020-01-16
US20180353504A1 (en) 2018-12-13
WO2018226942A1 (en) 2018-12-13
US20220233524A1 (en) 2022-07-28
CL2022002564A1 (es) 2023-05-26
KR20200018580A (ko) 2020-02-19
CL2019003572A1 (es) 2020-04-24
EP3634415A1 (en) 2020-04-15
AU2023282222A1 (en) 2024-01-04
BR112019025987A2 (pt) 2020-06-30
JP2020523312A (ja) 2020-08-06
CA3066398A1 (en) 2018-12-13
MX2019014748A (es) 2020-08-03
CN117122600A (zh) 2023-11-28
RU2019144001A (ru) 2021-07-09
CL2022002566A1 (es) 2023-05-26
CN110996954A (zh) 2020-04-10
SG11201911750RA (en) 2020-01-30
EP3634415A4 (en) 2021-03-17
WO2019236148A1 (en) 2019-12-12
AU2018279074B2 (en) 2023-12-14
RU2019144001A3 (es) 2022-03-05

Similar Documents

Publication Publication Date Title
MX2022008478A (es) Combinaciones de brimonidina de dosis baja y usos de las mismas.
MX2022000711A (es) Inhibidores de parp1.
MY196909A (en) Boronic acid derivatives and therapeutic uses thereof
GEP20217248B (en) 2,4,5-trisubstituted 1,2,4-triazolones useful as inhibitors of dhodh
PH12016500871A1 (en) Combination therapy including an mdm2 inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers
PH12016500024A1 (en) Bromodomain inhibitor
BR112015020389A2 (pt) compostos carbazol úteis como inibidores de bromodomínio
EA201690962A1 (ru) Составы
EA201691808A1 (ru) Кортикостероидные композиции для местного применения
EA201990424A1 (ru) Спиролактамовые модуляторы nmda-рецептора и их применение
EA201990428A1 (ru) Спиролактамовые модуляторы nmda-рецептора и их применение
PH12016502352A1 (en) Pharmaceutical composition
MX2018004664A (es) Antagonistas de ep4.
PH12019502150A1 (en) Compounds and methods for the treatment of parasitic diseases
MX2022001796A (es) Metodos y composiciones para inhibir los sintomas asociados con la veisalgia.
MX2018004304A (es) DERIVADOS DE QUINOXALINA Y PIRIDOPRAZINA COMO INHIBIDORES DE PI3Kß.
EA201791814A1 (ru) Имидазолильные трициклические еноны как антиоксидантные модуляторы воспаления
WO2019043176A3 (en) HISTONE-DEACETYLASE INHIBITOR IN COMBINATION WITH ANTIMETABOLITE AGENT FOR CANCER THERAPY
MX2019010218A (es) Derivados de pirazol como inhibidores de bromodominio.
BR112019017314A2 (pt) composições farmacêuticas para terapia de combinação
MX2018015240A (es) Composiciones que comprenden timolol y su uso en el tratamiento de rosacea mediante administracion topica.
UY37316A (es) Dispersión sólida farmacéutica de un inhibidor de bcl-2, composiciones farmacéuticas de ésta, y usos para el tratamiento de cáncer
WO2018062876A3 (ko) 통증이 경감되는 골관절염 치료용 키트
MX2018006631A (es) Compuesto para uso en la prevencion y tratamiento de enfermedades neurodegenerativas.
TR201719926A2 (tr) Farmasöti̇k olarak kabul edi̇lebi̇li̇r li̇tyum tuzlari ve c vi̇tami̇ni̇ i̇çeren farmasöti̇k bi̇leşi̇mler